Skip to main content

Table 1 Clinical data of the patients included in the study

From: EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation

  Tumors Patients
  tumor ID prominence [mm] LBD [mm] SBD [mm] cell type ciliary body involvement chr.3 status chr.8 alteration EFS methylation patient ID age at diagnosis [years] sex survival metastatic death follow up time [months]
set I T1 5.9 11.9 11.7 sc no D3 AI no 28914 69 m alive - 51
  T2 5.8 11.2 10.6 sc no D3 AI no 28101 69 f alive - 57
  T3 14.0 19.0 n.d. sc no D3 AI no 25722 48 f alive - 67
  T4 9.2 20.9 20.8 ec no D3 AI partial 29311 39 m deceased yes 18
  T5 11.4 19.0 11.9 sc no D3 no full 29802 66 f alive - 47
  T6 15.6 15.3 14.5 sc no D3 AI no 22978 50 f alive - 81
  T7 9.2 10.0 8.7 sc no D3 AI no 29101 64 f alive - 52
  T8 11.7 13.5 12.2 sc no D3 AI partial 29380 72 m alive - 51
  T9 10.8 n.d. n.d. sc no M3 AI full 30545 65 m alive - 46
  T10 12.0 13.4 11.9 sc no M3 no partial 27745 67 f deceased no 45
  T11 10.3 21.9 21.1 mc yes M3 AI full 24905 66 m deceased yes 26
  T12 9.8 17.0 13.5 mc no M3 AI full 24903 64 f deceased yes 43
  T13 10.6 21.3 17.4 mc no M3 AI full 25726 57 m deceased yes 19
  T14 9.8 25.0 21.0 sc yes M3 AI full 24464 62 m deceased yes 22
  T15 11.3 15.5 11.6 sc yes M3 AI full 27587 61 f deceased yes 20
  T16 8.5 n.d. n.d. sc yes M3 AI full 25243 62 m deceased yes 18
set II T17 7.1 11.2 10.6 sc yes D3 AI no 14514 58 f alive - 125
  T18 9.9 16.0 11.9 sc yes D3 AI no 17003 55 m alive - 112
  T19 10.4 15.5 14.4 sc no D3 AI no 17453 19 f alive - 110
  T20 9.8 16.1 14.5 sc yes D3 AI no 18671 46 f alive - 104
  T21 8.4 8.8 8.7 mc no D3 no partial 19207 69 m alive - 102
  T22 n.d. 9.4 8.6 sc no D3 no no 21436 38 m alive - 89
  T23 10.7 17.2 14.5 sc no D3 no no 31091 63 m alive - 44
  T24 16.2 21.3 17.2 sc no D3 AI no 31412 45 m alive - 39
  T25 6.0 13.4 12.1 sc n.d. D3 n.d. no 33708 68 m alive - 29
  T26 12.5 12.1 9.8 sc no D3 no no 36500 73 f alive - 20
  T27 12.0 22.7 18.9 sc no M3 AI partial 17451 68 m deceased no 37
  T28 10.5 24.3 19.6 mc yes M3 no full 18465 77 m deceased yes 37
  T29 12.3 16.0 15.2 mc no M3 AI full 20012 76 m deceased yes 6
  T30 10.7 17.7 16.6 mc yes M3 AI full 21501 71 m deceased yes 46
  T31 11.3 n.d. n.d. mc yes M3 AI full 22095 74 m deceased yes 2
  T32 11.9 16.9 15.4 sc no M3 AI full 22543 69 m deceased yes 5
  T33 9.3 20.0 n.d. mc no M3 no full 22805 70 m deceased no 18
  T34 10.6 15.8 15.5 sc yes M3 AI full 25720 61 m deceased yes 50
  T35 13.7 n.d. n.d. sc no M3 AI partial 26072 76 m alive - 61
  T36 11.3 11.4 7.0 mc yes M3 AI full 27766 63 m deceased yes 35
  T37 10.1 12.9 10.7 sc yes M3 AI full 29132 69 f alive - 52
  T38 10.1 20.4 16.5 sc nd M3 no full 29337 74 f alive - 51
  T39 13.6 18.0 14.5 mc no M3 AI full 32516 50 f deceased yes 30
  T40 8.3 12.5 11.5 mc no M3 AI full 34922 54 f alive - 24
  1. Methylation status of EFS as determined by direct sequencing of PCR products from bisulfite treated DNA; LBD, largest tumor diameter; SBD, smallest tumor diameter; M3, monosomy 3; D3, normal (retention of both alleles) chromosome 3 status; AI, allelic imbalance; m, male; f, female; sc, spindle cell; mc, mixed cell; ec, epitheloid cell type; n.d., not determined.